Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 5, 2015, Pages 201.e1-201.e8

  de Cobelli, Ottavio ^a   Terracciano, Daniela ^b   Tagliabue, Elena ^a   Raimondi, Sara ^a   Galasso, Giacomo ^a   Cioffi, Antonio ^a   Cordima, Giovanni ^a   Musi, Gennaro ^a   Damiano, Rocco ^c   Cantiello, Francesco ^c   Detti, Serena ^a   Victor Matei, Deliu ^a   Bottero, Danilo ^a   Renne, Giuseppe ^a   Ferro, Matteo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Active surveillance; Body mass index; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BODY MASS; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DISEASE COURSE; GLEASON SCORE; HUMAN; LOW RISK PATIENT; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SEMINAL VESICLE; TUMOR INVASION; TUMOR VOLUME;

EID: 84929293835     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.02.004     Document Type: Article

References (24)

1. Bastian P.J., Carter B.H., Bjartell A., Seitz M., Stanislaus P., Montorsi F., et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009, 55:1321-1330.
2. Klotz L., Zhang L., Lam A., Nam R., Mamedov A., Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
3. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
4. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
5. Allott E.H., Masko E.M., Freedland S.J. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013, 63:800-809.
6. Bangma C.H., Bul M., Roobol M. The Prostate Cancer Research International: active surveillance study. Curr Opin Urol 2012, 22:216-221.
7. van der Kwast T.H., Amin M.B., Billis A., Epstein J.I., Griffiths D., Humphrey P.A., et al. International Society of Urological Pathology (ISUP) Consensus Conference on handling and staging of radical prostatectomy specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011, 24:16-25.
8. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 29:1228-1242.
9. Villa L., Salonia A., Capitanio U., Scattoni V., Abdollah F., Suardi N., et al. The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting. Urology 2014, 84:634-641.
10. Bul M., Zhu X., Valdagni R., Pickles T., Kakehi Y., Rannikko A., et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013, 63:597-603.
11. Scattoni V., Zlotta A., Montironi R., Schulman C., Rigatti P., Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007, 52:1309-1322.
12. Iremashvili V., Soloway M.S., Rosenberg D.L., Manoharan M. Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol 2012, 187:1594-1599.
13. Banez L.L., Hamilton R.J., Partin A.W., Vollmer R.T., Sun L., Rodriguez C., et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. J Am Med Assoc 2007, 298:2275-2280.
14. Freedland S.J., Isaacs W.B., Mangold L.A., Yiu S.K., Grubb K.A., Partin A.W., et al. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res 2005, 11:2883-2888.
15. Efstathiou J.A., Chen M.H., Renshaw A.A., Loffredo M.J., D'Amico A.V. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer 2007, 109:1493-1498.
16. Terracciano D., Bruzzese D., Ferro M., Mazzarella C., Di Lorenzo G., Altieri V., et al. Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts Gleason sum upgrading. Prostate 2012, 72:100-107.
17. Freedland S.J., Sokoll L.J., Platz E.A., Mangold L.A., Bruzek D.J., Mohr P., et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 2005, 174:1266-1270.
18. Burton A., Martin R.M., Holly J., Lane J.A., Donovan J.L., Hamdy F.C., et al. Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes Control 2013, 24:323-334.
19. Cao Y., Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011, 4:486-501.
20. Kane C.J., Bassett W.W., Sadetsky N., Silva S., Wallace K., Pasta D.J., et al. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol 2005, 173:732-736.
21. Amling C.L., Kane C.J., Riffenburgh R.H., Ward J.F., Roberts J.L., Lance R.S., et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 2001, 58:723-728.
22. Siddiqui S.A., Inman B.A., Sengupta S., Slezak J.M., Bergstralh E.J., Leibovich B.C., et al. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer 2006, 107:521-529.
23. Loeb S., Yu X., Nadler R.B., Roehl K.A., Han M., Hawkins S.A., et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?. J Urol 2007, 177:102-106. [discussion 6].
24. Bhindi B., Kulkarni G.S., Finelli A., Alibhai S.M., Hamilton R.J., Toi A., et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol 2014, 66:841-848.